Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hip OA

New Findings on Hydroxychloroquine, Denosumab

Ruth Jessen Hickman, MD  |  November 12, 2020

ACR Convergence 2020—At two plenary sessions, speakers highlighted key findings, including results on the QTc interval in patients on hydroxychloroquine, and data from a study on denosumab vs. alendronate for glucocorticoid-induced osteoporosis. The QTc Interval & Hydroxychloroquine The safety profile and optimal dosing of hydroxychloroquine has been a topic for decades because it is known…

Filed under:ACR ConvergenceConditionsDrug UpdatesMeeting ReportsOsteoarthritis and Bone DisordersRheumatoid Arthritis Tagged with:ACR Convergence 2020bone mineral density (BMD)COVID-19denosumabFracturesHydroxychloroquine (HCQ)Osteoporosis

Pediatric Care, Disparity Awareness Among Rheumatology Research Foundation-Funded Studies Underway

Carina Stanton  |  November 10, 2020

Investigators are tackling rheumatology practice challenges, assessing what drives career choices in pediatric rheumatology, improving fellowship training and more—all with the support of the Rheumatology Research Foundation.

Filed under:ConditionsPediatric ConditionsResearch Rheum Tagged with:DisparitiesfellowshipPediatricRheumatology Research FoundationTransitions

We Are Rheumatology: Rheumatology Must Continue to Overcome the Challenges of the Pandemic

Vaneet K. Sandhu, MD, FACR, RhMSUS  |  November 10, 2020

Vaneet K Sandhu, MD, FACR, RhMSUS, discusses how rheumatologists should persevere and collaborate with colleagues to overcome the challenges of the pandemic.

Filed under:Professional Topics Tagged with:COVID-19Editorials/commentary from experts

ACR Convergence 2020: Study Data for Lupus & Rheumatoid Arthritis

Ruth Jessen Hickman, MD  |  November 9, 2020

ACR CONVERGENCE 2020—At the annual meeting’s second Plenary Session, Saturday, Nov. 7, speakers highlighted phase 2 results of a potential new biologic for systemic lupus erythematosus (SLE), as well as data on remission maintenance in rheumatoid arthritis (RA) after withdrawal of etanercept or methotrexate. Phase 2 Trial of Monoclonal Antibody for Lupus (LILAC) Several converging…

Filed under:ACR ConvergenceConditionsMeeting ReportsRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:ACR Convergence 2020ACR Convergence 2020 - SLEACR Convergence 2020 – RA

ACR Convergence 2020: COVID-19 Hyper-Inflammation in Kids

Jason Liebowitz, MD, FACR  |  November 9, 2020

ACR CONVERGENCE 2020—Among the many ways in which the COVID-19 pandemic has changed the face of modern medicine is the emergence of multisystem inflammatory syndrome in children (MIS-C), a rare but serious condition that shares many features of Kawasaki disease (KD). With this topic in mind, leading pediatric experts from around the world came together…

Filed under:ACR ConvergenceConditionsMeeting ReportsPediatric Conditions Tagged with:ACR Convergence 2020COVID-19Multisystem Inflammatory Syndrome in Children (MIS-C)

Under Pressure: An Update on Pulmonary Hypertension

Jason Liebowitz, MD, FACR  |  November 9, 2020

ACR CONVERGENCE 2020—In patients with connective tissue diseases, such as systemic sclerosis (SSc), pulmonary hypertension (PH) remains one of the leading causes of morbidity and mortality. In her lecture on Friday, Nov. 6, Pulmonary Hypertension: An Update, Mardi Gomberg-Maitland, MD, MSc, professor of medicine and medical director of the Pulmonary Hypertension Program at The George…

Filed under:ACR ConvergenceConditionsMeeting ReportsSystemic Sclerosis Tagged with:ACR Convergence 2020pulmonary arterial hypertension

The Great Debate: Should Jakinibs Be Used Before Biologics after Methotrexate Failure in RA?

Jason Liebowitz, MD, FACR  |  November 9, 2020

ACR CONVERGENCE 2020—In many ways, the current plethora of treatment options for rheumatoid arthritis patients represents an embarrassment of riches. However, while many therapeutics approved by the U.S. Food & Drug Administration (FDA) are available, knowing the order in which to try these medications with patients can be quite challenging. In The Great Debate, held…

Filed under:ACR ConvergenceDrug UpdatesMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2020ACR Convergence 2020 – RA

ACR Convergence 2020: Studies in Rheumatoid Arthritis

Keri Losavio  |  November 8, 2020

ACR CONVERGENCE 2020—Moderated by Bill St.Clair, MD, MACR, an ACR past president and a professor of medicine and immunology at Duke University Medical Center, Durham, N.C., an abstract session on Friday, Nov. 6, focused on the diagnosis, manifestations and outcomes of rheumatoid arthritis (RA), with a focus on interstitial lung disease. RA with ILD Jeffrey…

Filed under:ACR ConvergenceConditionsMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2020ACR Convergence 2020 – RA

Incoming ARP President Christine Stamatos, DNP, ANP-C, Ready to Advance Education & Engagement for Rheumatology Professionals

Carina Stanton  |  November 6, 2020

Christine Stamatos brings a combined focus on advanced education and service to connect and mobilize rheumatology professionals in these challenging times.

Filed under:American College of RheumatologyProfiles Tagged with:ARP presidentAssociation of Rheumatology Professionals (ARP)Dr. Christine Stamatos

Incoming ACR President David Karp, MD, PhD, Eager to Move Forward on Workforce Shortage, Workplace Bias & Member Engagement

Carina Stanton  |  November 6, 2020

With extensive leadership experience in practice and through many roles with the ACR’s committees, executive board of directors and Rheumatology Research Foundation, Dr. Karp is ready to address workforce shortages, workplace bias and member engagement to ensure a strong future for the College through COVID-19 and beyond.

Filed under:American College of RheumatologyProfiles Tagged with:ACR presidentDr. David KarpLeadership

  • « Previous Page
  • 1
  • …
  • 114
  • 115
  • 116
  • 117
  • 118
  • …
  • 330
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences